Modern treatment of allergic conjunctivitis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents allergic conjunctivitis as an allergic disease affecting the occular surface and it’s modern treatment.

Full Text

Restricted Access

About the authors

S M Shvets

Institute of Immunology, Moscow

Email: smshvets@gmail.com

References

  1. Ono S.J., Abelson M.B. Allergic conjunctivitis update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol. 2005, v. 115 (1), p. 118-122.
  2. Butrus S., Portela R. Ocular allergy: Diagnosis and treatment. Ophthalmol. Clin. North Am. 2005, v. 18, p. 485-492.
  3. Singh K., Axelrod S., Bielory L. The epidemiology of ocular and nasal allergy in the United States,1988—1994. J. Allergy Clin. Immunol. 2010, v. 126, p. 778-783.
  4. Ibбсez M.D., Garde J.M. Allergy in patients under fourteen years of age in Alergolygica. J. Invest Allergol. Clin. Immunol. 2009, v. 19, Suppl 2, p. 61-68.
  5. О.М. Курбачева, К.С. Павлова. Аллергический конъюнктивит: современный взгляд на проблему. Росс. Аллергол. Журн. 2011, № 1, с. 92-97.
  6. Kari O., Salo O.P., Halmepuro L., Suvilehto K. Tear histamine during allergic conjunctivitis challenge. Graefes Arch. Clin. Exp. Ophthalmol. 1985, v. 223 (2), p. 60-62.
  7. Berger W.E., Lanier B.Q., Abelsn M.B. Evaluation ofthe effect of an adjuvant therapy of olopatadine HCl 0,1% ophthalmic solution on quality of life of patients with allergic rhinitis using systemic and/or nasal therapy. Presented at: ACAAI; November 12—17, Boston, Mass. 2004.
  8. Crampton M.D. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Clin. Ther. 2002, v. 24, p. 1800-1808.
  9. Abelson M.B., Turner D. A randomized, double blind, parallel group comparison of olopatadine 0,1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin. Ther. 2003, v. 25, p. 931-946.
  10. Scadding G., Keith P.K. Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Expert Opin. Pharmacother. 2008, v. 9, No. 15, p. 2707-2715.
  11. Bonini S., Sgrulletta R., Coassin M., Bonini S. Allergic conjunctivitis: update on its pathophysiology and perspectives for future treatment. Pawankar et al. Allergy Frontiers: Clinical Manifestations. Springer. 2009, p. 25-47.
  12. Anderson D.F., MacLeod J.D., Baddeley S.M. et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin. Exp. Allergy. 1997, v. 27, p. 1060-1066.
  13. Н.Э. Леппенен, А.Н. Пампура. Аллергические конъюнктивиты у детей: от патогенеза к терапии. Росс. Аллергол. Журн. 2012, № 1, с. 70-74.
  14. Chigbu D.I. The pathophysiology of ocular allergy: A review. Cont Lens Anterior Eye. 2009, v. 32, p. 3-15.
  15. Manzouri B., Flynn T.H., Larkin F., Ono S.J., Wyse R. Pharmacotherapy of allergic eye disease. Expert Opin. Pharmacother. 2006, v. 7, p. 1191-1200.
  16. Schmid K.L., Schmid L.M. Ocular allergy: Causes and therapeutic options. Clin. Exp. Optom. 2000, v. 83, p. 257-270.
  17. Mcgill J.I., Holgate S.T., Church M.K. Allergic eye disease mechanisms. Br. J. Ophthalmol. 1998, v. 82, p. 1203-1214.
  18. Майчук Ю.Ф., Ковалевская М.А., Бржеский В.В. и соавт. Синдром «красного глаза». Практическое руководство для врачей-офтальмологов. М., 2010, с. 82-83.
  19. Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, 228 с.
  20. Solomon A., Pe’er J., Levi-Schaffer F. Advances in ocular allergy: Basic mechanisms, clinical patterns and new therapies. Curr. Opin. Allergy Clin. Immunol. 2001, v. 1, p. 477-482.
  21. Leonardi A.A., Abelson M.B. Double-masked, randomized, placebo-controlled controlled clinical study of the mast cell stabilizing effect of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther. 2003, v. 25, p. 2539-2552.
  22. Deschenes J., Discepola M., Abelson M.B. Comparative evaluation of olopatadine ophthalmic solution (0,1%) versus ketorolac ophthalmic solution (0,5%) using the provocative antigen challenge model. Acta Ophthalmol. Scand. Suppl. 1999, v. 228, p. 47-52.
  23. Butrus S., Greiner J.V., Discepola M. et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0,1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 2000, v. 22, p. 1462-1472.
  24. Berdy G.J., Spangler D.L., Bensch G. et al. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0,1% ophthalmic solution and ketotifen fumarate 0,025% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 2000, v. 22, p. 826-833.
  25. Katelaris C.H., Ciprandi G., Missotten L. et al. International Olopatadine Study Group. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0,1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin. Ther. 2002, v. 24, p. 1561-1575.
  26. Spangler D.L., Bensch G., Berdy G.J. Evaluation of the efficacy of olopatadine hydrochloride 0,1% ophthalmic solution and azelastine hydrochloride 0,5% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 2001, v. 23, p. 1272-1280.
  27. Berdy G.J., Stoppel J.O., Epstein A.B. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0,2% ophthalmic suspension in the conjunctival allergen challenge model. Clin. Ther. 2002, v. 24, p. 918-929.
  28. Майчук Ю.Ф., Позднякова В.В., Якушина Л.Н. Опатанол (олопатадин 0,1%) в лечении аллергических заболеваний глаз. РМЖ. 2007, № 2, с. 63-67.
  29. Blaho K. Non-steroidal anti-inflammatory drugs: Current trends in pharmacology and therapeutics. J. Am. Optom. Assoc. 1992, v. 63, p. 875-878.
  30. Masferrer J.L., Kulkarni P.S. Cyclooxygenase-2 inhibitors: A new approach to the therapy of ocular inflammation. Surv. Ophthalmol. 1997, v. 41 (Suppl 2), p. 35-40.
  31. Blaho K. Non-steroidal anti-inflammatory drugs: Current trends in pharmacology and therapeutics. J. Am. Optom. Assoc. 1992, v. 63, p. 875-878. [PubMed: 1287072]
  32. Yaylali V., Demirlenk I., Tatlipinar S., Ozbay D., Esme A., Yildirim C. et al. Comparative study of 0,1% olopatadine hydrochloride and 0,5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol. Scand. 2003, v. 81, p. 378-382.
  33. Discepola M., Deschenes J., Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0,05% ophthalmic solution to ketorolac 0,5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol. Scand. Suppl. 1999, v. 228, p. 43-46.
  34. Fukushima A., Yamaguchi T., Ishida W., Fukata K., Liu F.T., Ueno H. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. Clin. Exp. Ophthalmol. 2006, v. 34, p. 347-353.
  35. Ebihara N., Ohashi Y., Uchio E., Okamoto S., Kumagai N., Shoji J. et al. A large prospective observational study of novel cyclosporine 0,1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 2009, v. 25, p. 365-372.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies